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Abstract
Intestinal metaplasia (IM) of the stomach is associated with a very small increased risk of developing gastric cancer.
Endoscopic surveillance has been proposed and advocated for populations at risk. Risk factors for IM include Helicobacter
pylori infection, high salt intake, smoking, alcohol consumption, and chronic bile reﬂux. IM tends to appear initially at the
antrum–corpus junction, especially at the gastric angularis. As atrophy and metaplastic changes advance, they extend to the
antrum and corpus. Gastric IM is categorized histopathologically into incomplete and complete types. Patients with
incomplete IM should undergo endoscopic gastric mapping to deﬁne the extent of IM and rule out dysplasia or
adenocarcinoma. In this video presentation, endoscopic and pathological ﬁndings in gastric IM and gastric mapping
techniques has been described. This article is part of an expert video encyclopedia.
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Video Related to this Article
Material
• Gastroscopes: Olympus GIF-Q180; Olympus America,
Center Valley, PA, USA.
Background and Endoscopic Procedure
Intestinal metaplasia (IM) of the stomach is associated with a
very small increased risk of developing gastric cancer. The in-
cidence of gastric cancer is high in Eastern Asia, Eastern Eur-
ope, and Andean–Latin America. In the United States, several
ethnic populations have a high cancer risk, including African-
Americans, Native Americans, and immigrants from high-risk
regions. Endoscopic surveillance has been proposed and ad-
vocated for populations at risk. The much lower incidence of
gastric cancer in the United States and other Western countries
does not justify a general surveillance program. There are no
widely accepted guidelines on the management of gastric IM.
Recently, the European Society of Gastrointestinal Endoscopy
and other European academic societies have developed
evidence-based guidelines on the management of patients
with gastric IM. The recommendations emphasize the in-
creased cancer risk in patients with gastric atrophy and IM
and the need for adequate staging in the case of high-grade
dysplasia (HGD).
Risk factors for IM include Helicobacter pylori infection,
high salt intake, smoking, alcohol consumption, and chronic
bile reﬂux. The development of gastric adenocarcinoma of the
intestinal type is thought to progress sequentially through four
stages: nonatrophic gastritis, multifocal atrophic gastritis, IM,
and dysplasia. Chronic H. pylori infection induces chronic
inﬂammation in the gastric mucosa, which may progress to
atrophy and IM; this is a precursor to gastric adenocarcinoma.
IM initially appears at the antrum–corpus junction, especially
at the gastric angularis. As atrophy and metaplastic changes
advance, they tend to extend to the antrum and corpus, and
dysplastic foci may eventually appear.
Gastric IM is categorized histopathologically into in-
complete and complete types. Incomplete IM resembles co-
lonic epithelium with multiple, irregular mucin droplets of
variable size in the cytoplasm and absence of a brush border.
Complete IM resembles small intestinal epithelium with
eosinophilic enterocytes, a brush border, goblet cells, and
variable Paneth cells. Helicobacter pylori colonization can be
patchy in complete IM type.
Patients with incomplete IM should undergo endoscopic
gastric mapping to deﬁne the extent of IM and to rule out
dysplasia or adenocarcinoma. Gastric mapping involves bi-
opsies of the six zones of the stomach (antrum greater curve,
antrum lesser curve, gastric angularis, body greater curve, body
lesser curve, and fundus) and any visible lesions. Biopsies from
each zone should be collected into a separate specimen bottle.
Complete IM is associated with a lower risk of gastric
cancer. Therefore, in the absence of other risk factors for gastric
cancer, patients with complete IM do not need long-term
endoscopic surveillance.
Elevated serum pepsinogen level has been proposed
as a marker of extensive gastric atrophy. Currently, there are no
reliable markers of gastric dysplasia or cancer. Patients with
HGD or carcinoma in situ conﬁrmed by at least two gastro-
intestinal pathologists should undergo surgical or endoscopic
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resection because of the high probability of coexisting or
metachronous invasive carcinoma. IM of the cardia and Bar-
rett’s esophagus differ in their risk for malignant
transformation.
Key Learning Points/Tips and Tricks
• IM of the stomach is associated with a very small increased
risk of developing gastric cancer.
• Risk factors for IM include:
J H. pylori infection
J High salt intake
J Smoking
J Alcohol consumption
J Chronic bile reﬂux
• High-risk populations for gastric cancers include the
following:
J Eastern Asian
J Eastern European
J Andean–Latin American
J In the United States:
– African-Americans
– Native Americans
– Immigrants from high-risk regions
• The development of intestinal type gastric adeno-
carcinoma is thought to progress sequentially through four
stages:
J Nonatrophic gastritis
J Multifocal atrophic gastritis
J IM
J Dysplasia
• Chronic H. pylori infection is considered the primary cause
of gastric cancer.
• IM foci develop at the antrum–corpus junction initially
and extend to the antrum and corpus.
• Gastric IM is categorized histopathologically into two types:
J Incomplete IM
– Resembles colonic epithelium
(a) Irregular mucin droplets of variable size in the
cytoplasm.
(b) Absence of a brush border
– Recommend endoscopic gastric mapping 7 endo-
scopic surveillance
J Complete IM
– Resembles small intestinal epithelium
(a) Eosinophilic enterocytes
(b) Brush border
(c) Goblet cells
(d) Variable Paneth cells
– Endoscopic surveillance is not recommended if
other risk factors for gastric cancer are absent.
• There are no widely accepted guidelines on the manage-
ment of gastric IM.
• Endoscopic surveillance is proposed and advocated for
populations at risk:
J Ethnic background
J Family history of gastric cancer
J Histological type and extension of IM
J Gastric atrophy and IM
• Elevated serum pepsinogen level has been proposed as a
marker of extensive gastric atrophy.
• IM of the cardia and Barrett’s esophagus differ in their risk
for malignant transformation.
Scripted Voiceover
Time
(min:sec)
Voiceover text
00:00 Intestinal metaplasia (IM) of the stomach is associated
with a very small increased risk of developing gastric
cancer.
00:11 Known risk factors for IM include Helicobacter pylori
infection, high salt intake, smoking, alcohol
consumption, and chronic bile reﬂux.
00:27 Histopathologically, gastric IM is sub-grouped into
incomplete and complete types.
00:36 Incomplete IM resembles colonic epithelium with irregular
mucin droplets and the absence of a brush border.
00:49 Complete IM resembles small intestinal epithelium with
eosinophilic enterocytes, a brush border, goblet cells,
and Paneth cells.
01:04 Patients with incomplete IM should undergo endoscopic
gastric mapping to deﬁne the extent of IM and to rule
out dysplasia or adenocarcinoma.
01:19 Gastric mapping involves biopsies of the six zones of the
stomach and any visible lesions.
01:30 Biopsies from each zone should be collected into a
separate specimen bottle.
01:39 Gastric mapping is also recommended during endoscopic
surveillance of gastric IM.
01:55 The development of gastric adenocarcinoma of the
intestinal type is thought to progress sequentially
through these four stages.
02:07 IM initially appears at the antrum–corpus junction,
especially at the gastric angularis.
02:19 As atrophy and metaplastic changes advance, they tend to
extend to the antrum and the corpus.
02:30 In this patient, the granular appearance of the gastric
mucosa is from H. pylori infection and gastric IM.
02:43 Frequently, the gastric IM is better visualized under digital
chromoendoscopy.
03:08 Antral biopsy in this case conﬁrmed the gastric IM.
03:28 Gastric IM can appear as a localized papule as in this case,
or can be found on random biopsy of the gastric antrum
or body.
03:58 In this patient with chronic active gastritis due to H. pylori
infection, multiple areas of gastric IM can be observed.
04:23 In addition to digital chromoendoscopy, gastric IM can be
further enhanced by mucosal application of contrast
agent.
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04:43 In this patient, gastric dysplastic polyps developed in the
setting of chronic active gastritis and gastric IM.
05:15 Gastric dysplastic chances can be observed in these
pathological images.
05:24 In patients with gastric IM, endoscopic surveillance is
proposed and advocated for at-risk populations
including ethnic background, family history of gastric
cancer, histologic type and extension of IM, gastric
atrophy and IM.
05:49 Thank you for your attention.
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